Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease
Part of paid clinical trials in Huntsville, Alabama.
- Sponsor
- Regeneron Pharmaceuticals
- Study ID
- NCT07271186
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Diabetic Kidney Disease (DKD)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- ALN-ANG3 — DRUGAdministered per the protocol
- Evinacumab — DRUGAdministered per the protocol
- ALN-ANG3 placebo — DRUGAdministered per the protocol
- Evinacumab placebo — DRUGAdministered per the protocol
Study Details
This study is researching experimental drugs called ALN-ANG3 and evinacumab (called "study drugs"). The study is focused on participants who have diabetic kidney disease. The aim of the study is to see how safe and effective the study drugs are. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times
Key Dates
- Start date
- Jan 9, 2026
- Status verified
- May 2026
- Primary completion
- Sep 24, 2027
- Completion
- Apr 7, 2028
Study Design
- Enrollment
- 270 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: ALN-ANG3 + evinacumab placebo
- Experimental: ALN-ANG3 + evinacumab
- Placebo Comparator: ALN-ANG3 placebo + evinacumab placebo
Primary Outcome Measure
Percent change in Urine Albumin to Creatinine Ratio (UACR) [ Time Frame: Baseline to Week 24 ]
Central Contacts
- Clinical Trials Administrator844-734-6643